Encompass Health

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $6.21 billion, up 9.5% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.41 billion, down 6.8% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.80 billion, up 19% from a year earlier.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to December 31, 2025: $0.16 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (August 6, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
• Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed February 26, 2026): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $26.4 million on the open market.SEC Form 4
• 599 institutional managers reported a position at June 30, 2026 (+18 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 1 (6 a year earlier).U.S. Department of Labor (OFLC)

Risk events (12 months): 1 — latest OSHA inspection, Jan 8, 2026 →

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Encompass Health yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)third_quarter 2026 · $0.0 million
2. Oct 20, 2026Lobbying
   Lobbying report (SCULLY ROSKEY AND MISSMAR)third_quarter 2026 · $0.1 million
3. Oct 19, 2026Lobbying
   Lobbying report (ENCOMPASS HEALTH CORPORATION (FKA HEALTHSOUTH CORPORATION))third_quarter 2026 · $0.2 million
4. Oct 16, 2026Lobbying
   Lobbying report (RS GROUP CONSULTING LLC)third_quarter 2026 · $0.0 million
5. Jul 20, 2026Lobbying
   Lobbying report (ENCOMPASS HEALTH CORPORATION (FKA HEALTHSOUTH CORPORATION))second_quarter 2026 · $0.3 million
6. Jul 20, 2026Lobbying
   Lobbying report (POWERS PYLES SUTTER & VERVILLE, P.C.)second_quarter 2026 · $0.0 million
7. Jul 20, 2026Lobbying
   Lobbying report (SCULLY ROSKEY AND MISSMAR)second_quarter 2026 · $0.1 million
8. Jul 16, 2026Lobbying
   Lobbying report (RS GROUP CONSULTING LLC)second_quarter 2026 · $0.0 million
9. Jun 1, 20268-K
   Material agreement signedItem 1.01
10. May 15, 20268-K
    Material agreement signedItem 1.01
11. May 11, 20268-K
    Shareholder vote resultsItem 5.07
12. Mar 10, 20268-K
    Material agreement signedItem 1.01
13. Mar 10, 20268-K
    Material agreement terminatedItem 1.02
14. Feb 26, 202610-K
    Annual report (10-K)0 risk factors added, 0 removed
15. Feb 20, 20268-K
    Director or officer changeItem 5.02
16. Feb 2, 20268-K
    Director or officer changeItem 5.02
17. Jan 8, 2026Risk event
    OSHA planned inspection: ENCOMPASS HEALTH CORPORATIONOSHA
18. Sep 18, 20258-K
    Director or officer changeItem 5.02
19. May 2, 20258-K
    Director or officer changeItem 5.02
20. May 2, 20258-K
    Shareholder vote resultsItem 5.07
21. Apr 24, 20258-K
    Director or officer changeItem 5.02
22. Feb 28, 202510-K
    Annual report (10-K)0 risk factors added, 2 removed
23. Feb 21, 20258-K
    Director or officer changeItem 5.02
24. Feb 28, 202410-K
    Annual report (10-K)3 risk factors added, 0 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

785161

LEI

549300FVRPM9DRQZRG64

Wikidata

Q5690400